我国药品集中采购制度“竞价分组”政策的评价与思考——基于2016年各省集中采购方案的统计分析  

Assessment and rational thinking of “Bidding Group”in Chinese centralized drug procurement system

作　　者：丁锦希[1] 董锐[1] 李伟[1] 龚博君 王君焱 DING Jin-xi DONG Rui LI Wei GONG Bo-jun WANG Jun-yan(School of Pharmaceutical Business of China Pharmaceutical University, Nanjing Jiangsu 211198, China China Resources Saike Pharmaceutical Co. , Ltd, Beijing 100124, China)

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198 [2]华润赛科药业有限责任公司,北京100124

出　　处：《中国卫生政策研究》2016年第9期52-59,共8页Chinese Journal of Health Policy

基　　金：2015年与2016年国家卫生与计划生育委员会委托课题(药政[2015]12号;药政[2016]11号)

摘　　要：2015年,国家相继出台药品集中采购制度改革文件,将药品质量作为改革的重点内容。药品集中采购制度主要利用竞价分组区分药品质量层次,达到"质量优先"的目的。但现阶段我国竞价分组存在层级划分不统一、指标构建不科学等问题,弱化了集中采购对药品质量的引导作用。本文以竞价分组作为研究对象,通过对各省(市)最新出台的采购文件中有关竞价分组的相关内容进行统计分析,发现竞价分组存在的主要问题,在此基础上探索我国竞价分组完善和优化的策略。In 2015 , policy reforms on centralized drug purchasing system have been released one by one , and the quality of medicines has been highly valued .Centralized drug purchasing system distinguishes different qualities of drugs mainly through bidding grouping , in order to achieve “uality priority”.However , there are yet some existing problems in group bidding policy at present , such as lack of a unified hierarchy , no scientific indicators and so on , which inevitably weaken the leading role of centralized purchasing policy over the quality of medicines .This paper , focuses on the study of group bidding , and the existing main problems are found through the statistical analysis of rel-evant policies introduced in different provinces .Finally, it explores some optimization strategies for “Group Bidding”which is of paramount importance .

关 键 词：药品集中采购 竞价分组 政策评价 

分 类 号：R197[医药卫生—卫生事业管理]